Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for Asilone returned no results
Showing 916 to 930 of 949 results for alone

  1. New agreement means NICE recommends combination treatment for some lymphoma patients

    Hundreds of people with a form of blood cancer will benefit from a new treatment following the publication of draft guidance by NICE.

  2. New drugs 'a major benefit' for patients with chronic hepatitis C

    NICE has recommended the use of boceprevir (Victrelis) and telaprevir (Incivo), both in combination with peginterferon alfa and ribavirin, as options for the treatment of the most common strain of hepatitis C in adults, in latest guidance.

  3. NICE draft guidance extends recommendation for sapropterin to pregnant women and people aged up to 22 years with rare inherited metabolic condition phenylketonuria

    NICE has today (20 August 2021) issued final draft guidance which now recommends sapropterin (also called Kuvan and made by BioMarin) as an option for treating phenylketonuria (PKU) in pregnant women until they give birth as well as for treating the condition in people until they turn 22.

  4. NICE approves ground-breaking cholesterol-lowering drug inclisiran

    NICE has today (1 September 2021) issued draft final guidance recommending the novel anti-cholesterol drug inclisiran (Leqvio and made by Novartis) for people with primary hypercholesterolaemia or mixed dyslipidaemia who have already had a cardiovascular event such as a heart attack or stroke.

  5. Minimum pricing for alcohol 'effectively targets harmful drinkers'

    A minimum price per unit of alcohol, as recommended by NICE, effectively targets high-risk drinkers while having little impact on moderate drinkers, according to a new study.

  6. First treatment to target heart condition set to benefit thousands as NICE draft guidance approves NHS use

    NICE has approved mavacamten, the first treatment that specifically targets a heart condition called obstructive hypertrophic cardiomyopathy (HCM). It means around 7,000 people will now be able to access the treatment on the NHS.

  7. Drug recommended to help cut drink dependence

    NICE has approved the use of nalmefene to help people who are dependent on alcohol to cut down on the amount they drink.

  8. Breast cancer patients to have further NICE-approved drug combination option on Cancer Drugs Fund

    Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on the Cancer Drugs Fund (CDF) following its approval by NICE in final guidance published today (15 January 2020).

  9. Hundreds of people with some forms of urothelial cancer to receive new treatment

    Over 800 people with locally advanced or metastatic urothelial cancer are set to benefit from a new treatment – avelumab – following its recommendation for routine NHS funding in final draft guidance published today (Thursday 7 April) by NICE.

  10. Age 'should not be barrier to treatment'

    Decisions around whether to offer a person surgical treatment should not be based on age and fitness, according to a new report.

  11. Digital and mobile interventions could support regular health services in helping people stop smoking and reduce their risk of obesity, says NICE

    Health professionals can consider digital and mobile interventions as a supplement to regular services to support behaviour change in people at risk of developing chronic conditions.

  12. NICE recommends new 'chemotherapy-free' treatment for lymphoma

    A new treatment option for patients with previously treated follicular lymphoma (grade 1 to 3A) has been approved by NICE.

  13. NICE recommends new drug for people living with obesity

    Thousands of people living with obesity are set to benefit from a new drug which has helped those using it to reduce their weight by more than 10 per cent.

  14. NICE recommends new treatment option for adults with obesity and non-diabetic hyperglycaemia who have a high risk of cardiovascular disease

    All eligibility criteria must be met for Liraglutide to be offered

  15. NICE recommends rivaroxaban to prevent blood clots in patients who have had a heart attack

    Rivaroxaban (Xarelto), in combination with clopidogrel and aspirin, or with aspirin alone, can now be used as an option for preventing blood clots in people who have had an acute coronary syndrome, following latest guidance.